Benitec Biopharma (BNTC, Financial) has garnered attention as HC Wainwright & Co. analyst Raghuram Selvaraju reaffirms a "Buy" rating on the stock. This latest evaluation highlights the continued confidence of the financial services firm in BNTC's market performance and business potential.
According to the most recent update from HC Wainwright & Co., the price target for Benitec Biopharma (BNTC, Financial) remains unchanged at USD 28.00. This positioning indicates no alteration from the previous price target set for BNTC, maintaining the outlook established by the analyst.
HC Wainwright & Co.'s reinforcement of the "Buy" rating for Benitec Biopharma (BNTC, Financial) on May 19, 2025, underscores a steady belief in the company's growth trajectory. The decision reflects an unchanged outlook from the past assessments, consistent with the previous ratings provided by the firm.
Investors and market participants tracking Benitec Biopharma (BNTC, Financial) will note that the reaffirmed price target and rating offer a stable perspective amid the dynamic market conditions. As always, stakeholders are encouraged to consider multiple sources when evaluating potential stock investments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Benitec Biopharma Inc (BNTC, Financial) is $25.71 with a high estimate of $35.00 and a low estimate of $17.00. The average target implies an upside of 89.08% from the current price of $13.60. More detailed estimate data can be found on the Benitec Biopharma Inc (BNTC) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Benitec Biopharma Inc's (BNTC, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Benitec Biopharma Inc (BNTC, Financial) in one year is $0.21, suggesting a downside of 98.46% from the current price of $13.6. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Benitec Biopharma Inc (BNTC) Summary page.
